DGMT service contract on PacBio Revio sequencer

The Food and Drug Administration has issued a forecast for a service contract covering the PacBio Revio next-generation sequencing instrument, which includes an initial base period and up to three optional extension periods. The contract is intended to provide comprehensive maintenance, technical support, and operational services to ensure the continuous and reliable performance of the sequencing platform. The North American Industry Classification System code 811219 indicates this is for other commercial and industrial machinery and equipment repair and maintenance services, aligning with the need for specialized technical expertise required for the advanced sequencing technology. The point of contact for program inquiries is the Nctr Acquisition Liaison, reachable via nctracquisitions@fda.hhs.gov, while the contracting officer position is currently listed as to be determined. The place of performance and organizational address details have not been specified, suggesting that services may be delivered remotely or at multiple FDA facilities. The forecast was posted on May 25, 2026, and no set-aside designation has been applied, indicating the opportunity is open to all eligible vendors. This contract anticipates long-term support through potential multi-year extensions to maintain the instrument’s high-performance capabilities over an extended operational lifecycle.